BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 15188458)

  • 1. Analysis of cytogenetic alterations in stage III serous ovarian adenocarcinoma reveals a heterogeneous group regarding survival, surgical outcome, and substage.
    Partheen K; Levan K; Osterberg L; Helou K; Horvath G
    Genes Chromosomes Cancer; 2004 Aug; 40(4):342-8. PubMed ID: 15188458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognosis of stage III or IV primary peritoneal serous papillary carcinoma.
    Dubernard G; Morice P; Rey A; Camatte S; Fourchotte V; Thoury A; Pomel C; Pautier P; Lhommé C; Duvillard P; Castaigne D
    Eur J Surg Oncol; 2004 Nov; 30(9):976-81. PubMed ID: 15498644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative genomic hybridization detects frequent overrepresentation of chromosomal material from 3q26, 8q24, and 20q13 in human ovarian carcinomas.
    Sonoda G; Palazzo J; du Manoir S; Godwin AK; Feder M; Yakushiji M; Testa JR
    Genes Chromosomes Cancer; 1997 Dec; 20(4):320-8. PubMed ID: 9408747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chromosomal losses of regions on 5q and lack of high-level amplifications at 8q24 are associated with favorable prognosis for ovarian serous carcinoma.
    Staebler A; Karberg B; Behm J; Kuhlmann P; Neubert U; Schmidt H; Korsching E; Bürger H; Lelle R; Kiesel L; Böcker W; Shih IeM; Buchweitz O
    Genes Chromosomes Cancer; 2006 Oct; 45(10):905-17. PubMed ID: 16845658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of chromosomal alterations in bladder transitional cell carcinomas from Northern China by comparative genomic hybridization.
    Qin SL; Chen XJ; Xu X; Shou JZ; Bi XG; Ji L; Han YL; Cai Y; Wei F; Ma JH; Wu M; Zhan QM; Wang MR
    Cancer Lett; 2006 Jul; 238(2):230-9. PubMed ID: 16125302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chromosomal aberrations detected by comparative genomic hybridization predict outcome in patients with colorectal carcinoma.
    Liu XP; Kawauchi S; Oga A; Sato T; Ikemoto K; Ikeda E; Sasaki K
    Oncol Rep; 2007 Jan; 17(1):261-7. PubMed ID: 17143507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trisomy 8 in stage I and stage III ovarian cancer detected by fluorescence in situ hybridization.
    Mark HF; Afify AM; Werness BA; Das S; Mark S; Samy M
    Exp Mol Pathol; 1999 Apr; 66(1):76-81. PubMed ID: 10331967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Micropapillary serous carcinoma of the ovary has distinct patterns of chromosomal imbalances by comparative genomic hybridization compared with atypical proliferative serous tumors and serous carcinomas.
    Staebler A; Heselmeyer-Haddad K; Bell K; Riopel M; Perlman E; Ried T; Kurman RJ
    Hum Pathol; 2002 Jan; 33(1):47-59. PubMed ID: 11823973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Testing of two binary grading systems for FIGO stage III serous carcinoma of the ovary and peritoneum.
    Seidman JD; Horkayne-Szakaly I; Cosin JA; Ryu HS; Haiba M; Boice CR; Yemelyanova AV
    Gynecol Oncol; 2006 Nov; 103(2):703-8. PubMed ID: 16828848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative genome hybridization reveals specific genomic imbalances during the genesis from benign through borderline to malignant ovarian tumors.
    Helou K; Padilla-Nash H; Wangsa D; Karlsson E; Osterberg L; Karlsson P; Ried T; Knutsen T
    Cancer Genet Cytogenet; 2006 Oct; 170(1):1-8. PubMed ID: 16965948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Study of ovarian cancer management.
    Gaughan E; Javaid T; Cooley S; Byrne P; Gaughan G
    Ir Med J; 2006 Oct; 99(9):279-80. PubMed ID: 17144239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of cytoreduction in stage III and IV uterine papillary serous carcinoma.
    Thomas MB; Mariani A; Cliby WA; Keeney GL; Podratz KC; Dowdy SC
    Gynecol Oncol; 2007 Nov; 107(2):190-3. PubMed ID: 17825394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. VEGF-A and i-NOS expression are prognostic factors in serous epithelial ovarian carcinomas after complete surgical resection.
    Engels K; du Bois A; Harter P; Fisseler-Eckhoff A; Kommoss F; Stauber R; Kaufmann M; Nekljudova V; Loibl S
    J Clin Pathol; 2009 May; 62(5):448-54. PubMed ID: 19126566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microdissection-based mutational genotyping of serous borderline tumors of the ovary.
    Krishnamurti U; Sasatomi E; Swalsky PA; Jones MW; Finkelstein SD
    Int J Gynecol Pathol; 2005 Jan; 24(1):56-61. PubMed ID: 15626917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.
    Winter WE; Maxwell GL; Tian C; Sundborg MJ; Rose GS; Rose PG; Rubin SC; Muggia F; McGuire WP;
    J Clin Oncol; 2008 Jan; 26(1):83-9. PubMed ID: 18025437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
    Silva EG; Gershenson DM; Malpica A; Deavers M
    Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chromosome imbalances in thyroid follicular neoplasms: a comparison between follicular adenomas and carcinomas.
    Roque L; Rodrigues R; Pinto A; Moura-Nunes V; Soares J
    Genes Chromosomes Cancer; 2003 Mar; 36(3):292-302. PubMed ID: 12557229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of heterozygosity at chromosome 9q22-31 is a frequent and early event in ovarian tumors.
    Byrom J; Mudaliar V; Redman CW; Jones P; Strange RC; Hoban PR
    Int J Oncol; 2004 May; 24(5):1271-7. PubMed ID: 15067351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Establishment and characterization of a serous papillary adenocarcinoma cell line of the human ovary in a serum-free culture.
    Emoto M; Oshima K; Ishiguro M; Iwasaki H; Kawarabayashi T; Kikuchi M
    Pathol Res Pract; 1999; 195(4):237-42. PubMed ID: 10337661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytogenetic analysis of carboplatin resistance in early-stage epithelial ovarian carcinoma.
    Osterberg L; Levan K; Partheen K; Helou K; Horvath G
    Cancer Genet Cytogenet; 2005 Dec; 163(2):144-50. PubMed ID: 16337857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.